Trial Profile
Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis: a Short-term, Prospective, Open-label, Efficacy and Safety Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Lanthanum carbonate (Primary)
- Indications Hyperoxaluria; Renal calculi; Urolithiasis
- Focus Therapeutic Use
- Acronyms LaCa
- 07 Jan 2021 Planned End Date changed from 1 May 2020 to 31 Dec 2022.
- 07 Jan 2021 Planned primary completion date changed from 1 May 2020 to 31 Dec 2022.
- 17 May 2018 Planned End Date changed from 1 Sep 2018 to 1 May 2020.